Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia

Giampaolo Bucaneve; Alessandra Micozzi; Marco Picardi; Stelvio Ballanti; Nicola Cascavilla; Prassede Salutari; Giorgina Specchia; Rosa Fanci; Mario Luppi; Laura Cudillo; Renato Cantaffa; Giuseppe Milone; Monica Bocchia; Giovanni Martinelli; Massimo Offidani; Anna Chierichini; Francesco Fabbiano; Giovanni Quarta; Valeria Primon; Bruno Martino; Annunziata Manna; Eliana Zuffa; Antonella Ferrari; Giuseppe Gentile; Robin Foà; A. Del Favero

doi:10.1200/jco.2013.51.6963

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The combination of piperacillin/tazobactam and tigecycline is safe, well tolerated, and more effective than piperacillin/tazobactam alone in febrile, high-risk, neutropenic hematologic patients with cancer. In epidemiologic settings characterized by a high prevalence of infections because of MDR microorganisms, this combination could be considered as one of the first-line empiric antibiotic therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bucaneve et al. (2014) studied this question.

synapsesocial.com/papers/69d9655400ab073a2783662e https://doi.org/10.1200/jco.2013.51.6963

View Full Paper

Ask AI

Bookmark

Share

Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia

Ask about this paper

Abstract

Discussion

Cite This Study

Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading